Comparing the current results to its competitors, Charles River Laboratories International Inc reported Revenue decrease in the 2 quarter 2026 year on year by -2.72 %, despite the revenue increase by the most of its competitors of 9.71 %, recorded in the same quarter.
Charles River Laboratories International inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 8.47 %
Charles River Laboratories International Inc 's Comment on Competition and Industry Peers
Charles River Laboratories International, Inc. operates in three business segments: Research Models and Services (RMS), Discovery Services and Assessment (DSA) discovery services, and DSA safety assessment services. In the RMS segment, its primary competitors include one government-funded not-for-profit entity, one division of a public U.S. company, one privately held U.S. company, and one public company based in China. The DSA discovery services segment faces competition from hundreds of companies, with two main competitors being a public company in China and a public company in Europe. In the DSA safety assessment services segment, there are dozens of competitors, including a division of a large public U.S. company and a private Canadian company. Additional competition arises from internal discovery and development teams within client organizations, as well as in-house departments at pharmaceutical and biotechnology companies, universities, and teaching hospitals. Endotoxin detection technology competitors include Celsis® and Endosafe® Trillium®.
June 6, 2024
Johnson Fistel, LLP Investigates Charles River Laboratories Directors and Officers for Breach of Fiduciary DutiesSan Diego, June 06, 2024 - Johnson Fistel, LLP, a shareholder rights law firm, has launched an investigation into potential breaches of fiduciary duties by certain directors and officers of Charles River Laboratories International, Inc. (NYSE: CRL). The probe seeks to determine whether these individuals acted in the best interests of the company and its shareholders.As a leading provider of research services, Charles River Laboratories plays a critical role in the pharmaceutical and biotech industries. The company s success relies heavily on the competence and integrity of its leadership. Johnson ...
March 27, 2024
Leading contract research organization, Charles River Laboratories International, Inc., continues to make innovative strides in environmental, social, and governance (ESG) initiatives, strategic collaborations, and corporate citizenship efforts, according to their recently published 2023 Corporate Citizenship Report.The report outlines key progress made by the firm from 2022 and 2023, focusing on four major strategic areas of ESG: Accelerating Life-Saving Therapies, Leading with Integrity, Inspiring our People, and Protecting our Planet. The commitments reiterated by the firm show a conscious elevation of responsible business practices, intertwining societal impact with core business pursuits. A notable mile...
March 21, 2024
Charles River Expands Alliances in Gene Therapy Manufacturing, Strengthening Capabilities and ServicesIn a move that further solidifies its position in the field of gene therapy manufacturing, Charles River Laboratories International, Inc. has announced a series of strategic alliances with leading institutions in the medical research and development sector. The company s recent collaborations with the National University of Singapore s Yong Loo Lin School of Medicine (NUS Medicine), Wheeler Bio, Inc., and Pluristyx Inc. underscore Charles River s commitment to expanding its portfolio of high-quality products and services in the evolving landscape of regenerative medicine.The first alliance, a High Quality pl...
March 14, 2024
Charles River Laboratories and Navega Therapeutics Enter Collaboration for Gene Therapy ManufacturingWILMINGTON, Mass. - Charles River Laboratories International, Inc. and Navega Therapeutics, Inc. have announced a comprehensive gene therapy manufacturing collaboration. As part of Charles River s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Navega will gain access to established contract development and manufacturing capabilities and advisory services. The collaboration aims to produce an adeno-associated virus (AAV)-based gene therapy.Under the agreement, Navega will benefit from Charles River s Cell and Gene Therapy Accelerator Program s contract development and manufacturing (CDMO) capabilities....
January 16, 2024
Charles River Laboratories Launches Innovative Plasmid Offering to Enhance Gene Therapy Manufacturing Efficiency in Collaboration with Genetic Cures for KidsWILMINGTON, Mass. - Charles River Laboratories International, Inc. (NYSE: CRL), a leading contract development and manufacturing organization (CDMO), has announced the introduction of their new off-the-shelf Rep/Cap plasmid offering. This innovative product is specifically designed to streamline adeno-associated virus (AAV)-based gene therapy programs, furthering the company s commitment to advancing the field of genetic medicine.The Rep/Cap plasmid offering complements Charles River s existing lentiviral packaging and AAV Helper plasmid products, provid...
November 28, 2023
Charles River Laboratories and Genetic Cures for Kids Join Forces in Groundbreaking Gene Therapy Manufacturing Collaboration WILMINGTON, Mass. - Charles River Laboratories International, Inc. (NYSE: CRL) and Genetic Cures for Kids Inc (GC4K), an innovative Australian non-profit foundation dedicated to research and clinical trials for rare diseases, have announced an exciting collaboration in the field of gene therapy manufacturing. This partnership showcases their shared commitment to finding cures that can transform the lives of children suffering from rare diseases. GC4K, founded in 2021 by Golden and Chris Whitrod, parents of Tallulah Moon, a remarkable 4-year-old girl facing a rare medical condit...
November 16, 2023
Charles River Expands Suite of Cellular Products with CliniPrime Cryopreserved Leukopaks, While Facing Revenue Growth Challenges Charles River Laboratories International, Inc. (NYSE: CRL), a leading provider of drug discovery and development services, has recently announced the launch of CliniPrime Cryopreserved Leukopaks, further expanding its suite of Good Manufacturing Practice (GMP)-compliant offerings for cell therapy development and manufacturing. This new addition to its product portfolio is in line with the company s commitment to meeting regulatory guidelines for clinical trial development and commercial manufacturing of advanced therapies. Gene-modified cell therapies have shown immense pot...
Publicly Traded Peers of Charles River Laboratories International inc
Iqvia Holdings Inc Share Performance
+15.20%
30 Days
Iqvia Holdings Inc
Profile
IQVIA Holdings Inc operates a multifaceted business model that focuses on delivering advanced analytics, technology solutions, and clinical research services tailored for the healthcare sector. By harnessing extensive data resources and industry expertise, the company aids clients in optimizing operations, enhancing drug development processes, and ultimately improving patient outcomes.
Inotiv Inc is a contract research organization (CRO) that provides preclinical and nonclinical research services to the pharmaceutical, biotechnology, and medical device companies. The company offers a range of services including drug discovery, safety assessment, toxicology testing, and analytical services. By assisting clients with their research and development needs, Inotiv aims to contribute to the advancement of medicine and the development of new treatment options.
Omniab Inc is a technology company that operates on a B2B (business-to-business) model, offering a range of software solutions and services. The company focuses on providing customized software applications to help businesses streamline their operations, enhance productivity, and improve efficiency. Omniab Inc also offers consultation services to assist companies in optimizing their IT infrastructure.
Pluri Inc's business model revolves around providing digital solutions and services to various clients. They leverage their expertise and technology to offer customized software development, IT consulting, and digital marketing services. With a focus on delivering tailored solutions, Pluri Inc aims to meet the specific needs and goals of their clients and support their growth in the digital landscape.
Rapid Micro Biosystems Inc has a business model centered around providing automated microbial detection and enumeration solutions for pharmaceutical companies, ensuring streamlined and efficient quality control processes. Their innovative technology enables rapid detection of microbial contamination in products, reducing the need for manual intervention and accelerating time-to-results for manufacturers.
Sources:
Charles River Laboratories International inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Charles River Laboratories International inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
